Abstract
Early reports that acyclic analogues of oxytocin and vasopressin (AVP) have drastically reduced agonistic activities established as dogma that an intact hexapeptide ring structure is essential for the pharmacological activities of analogues of neurohypophysial hormones1. Thus, virtually all the many hundreds of agonistic and antagonistic analogues of the neurohypophysial peptides that have been reported contain an intact ring1–3. Here we report that an intact ring is not essential for binding of antagonistic AVP analogues to vasopressor (V1) or antidiuretic (V2) AVP receptors. In fact, one acyclic AVP analogue seems to be about as potent as any previously reported cyclic V2 antagonist. This finding suggests new possibilities for the design of AVP analogues as pharmacological probes and for therapeutic use. Similar modifications might be useful in the design of analogues of other cyclic peptides, such as calcitonin, somatostatin and the atrial natriuretic factors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berde, B. & Boissonnas, R. A. in Handbook of Experimental Pharmacology Vol. 23 (ed. Berde, B.) 802–807 (Springer, Berlin, 1968).
Hruby, V. J. & Smith, C. W. in The Peptides Vol. 8 (eds Udenfriend, S. & Meienhofer, J.) 77–207 (Academic, Orlando, Florida, 1987).
Manning, M., Bankowski, K. & Sawyer, W. H. in Vasopressin, Principles and Properties (eds Gash, D. M. & Boer, G. J.) 335–368 (Plenum, New York, 1987).
Manning, M. et al. J. med. Chem. 25, 45–50 (1982).
Merrifield, R. B. J. Am. chem. Soc. 85, 2149–2154 (1963).
Merrifield, R. B. Science 232, 341–347 (1986).
Sawyer, W. H. Endocrinology 63, 694–698 (1958).
Sawyer, W. H. et al. Science 212, 49–51 (1981).
Dekanski, J. Br. J. Pharmac. 7, 567–572 (1952).
Dyckes, D. F., Nestor, J. J. Jr, Ferger, M. F. & du Vigneand, V. J. med. Chem. 17, 250–252 (1974).
Manning, M. & Sawyer, W. H. J. cardiovasc. Pharmac. Suppl. 8, 529–535 (1986).
Ali, F. E. et al. J. med. Chem. 29, 984–988 (1986).
Nelson, C. F. et al. J. med. Chem. 29, 2425–2426 (1986).
De Wied, D., Gaffori, O., van Ree, J. M. & de Jong, W. Nature 308, 276–278 (1984).
Johnston, C. I. J. Hypertension 3, 557–569 (1985).
Schrier, R. W. New Engl. J. Med. 312, 1121–1123 (1985).
Orlowski, R. C., Epand, R. M. & Stafford, A. R. Eur. J. Biochem. 163, 399–402 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manning, M., Przybylski, J., Olma, A. et al. No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 329, 839–840 (1987). https://doi.org/10.1038/329839a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/329839a0
This article is cited by
-
Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions
Current Hypertension Reports (2022)
-
The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists
International Journal of Peptide Research and Therapeutics (2007)
-
Sustained aquaretic effect of the V2‐AVP receptor antagonist, RWJ‐351647, in cirrhotic rats with ascites and water retention
British Journal of Pharmacology (2005)
-
Role of Arginine Vasopressin V1 and V2 Receptors for Brain Damage After Transient Focal Cerebral Ischemia
Journal of Cerebral Blood Flow & Metabolism (2005)
-
Novel strategies for the design of receptor‐selective vasopressin analogues: Aib‐substitution and retro‐inverso transformation
British Journal of Pharmacology (1999)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
